Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
US9526777B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9526777-B2 |
| Application number | US-201113641655-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 15, 2011 |
| Priority date | Apr 16, 2010 |
| Publication date | Dec 27, 2016 |
| Grant date | Dec 27, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inducing a protective immune response against an Ebola virus infection in a subject, the method comprising intramuscularly administering to the subject 10 10 to 10 12 viral particles of a recombinant chimpanzee adenovirus type 3 (ChAd3) vector comprising a nucleic acid encoding an Ebola virus glycoprotein, followed by administering to the subject a prophylactically effective amount of a modified vaccinia virus Ankara (MVA) vector comprising a nucleic acid encoding the Ebola virus glycoprotein. 2. The method of claim 1 , wherein the Ebola virus is of species Zaire. 3. The method of claim 2 , wherein the Ebola virus glycoprotein is encoded by a polynucleotide sequence as shown in SEQ ID NO:10 (Z GP wild-type). 4. The method of claim 1 , wherein the Ebola virus is of species Sudan/Gulu. 5. The method of claim 4 , wherein the Ebola virus glycoprotein is encoded by a polynucleotide sequence as shown in SEQ ID NO: 11 or 13 (S/G GP codon-optimized or wild-type).
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9526777B2 cover?
- This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).
- Who is the assignee on this patent?
- Sullivan Nancy J, Nabel Gary J, Asiedu Clement, and 7 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).